Intelligence ยท Patent portfolio
United Therapeutics Europe Patents
Full USPTO pharma patent portfolio for United Therapeutics Europe โ grant dates, expiration, and drug cross-links.
- Patents
- 3,720
- Expiring โค24m
- 234
Quick answer
United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months โ use filters for patent-cliff planning.
-
US 10570214
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
granted -
US 10562960
Neutralizing antibodies to gp120 and their use
granted -
US 10561724
Live attenuated virus vaccines for La Crosse virus and other bunyaviridae
granted -
US 10561722
Methods and compositions for enhancing immune responses
granted -
US 10562843
Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
granted -
US 10561673
Dendrimer based nanodevices for therapeutic and imaging purposes
granted -
US 10561721
Methods and compositions for inducing protective immunity against filovirus infection
granted -
US 10561729
Near-IR light-cleavable conjugates and conjugate precursors
granted -
US 10561666
Amido compounds as RORฮณt modulators and uses thereof
granted -
US 10562952
Anti-CD276 chimeric antigen receptors
granted -
US 10555961
Materials and methods for treating bacterial infections using C-1 gentamicin
granted -
US 10556001
Thermal inactivation of rotavirus
granted -
US 10555928
Cannabis extracts and methods of preparing and using same
granted -
US 10557118
Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
granted -
US 10556940
T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
granted -
US 10555942
Emetine compounds for treatment and prevention of flavivirus infection
granted -
US 10556916
Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography
granted -
US 10548984
RVG Derived peptides
granted -
US 10550164
Brachyury deletion mutants, non-yeast vectors encoding Brachyury deletion mutants, and their use
granted -
US 10548863
Process to prepare treprostinil, the active ingredient in Remodulinยฎ
granted -
US 10548987
Antibody-drug conjugates for targeting CD56-positive tumors
granted -
US 10548970
Human rotavirus G9P[6] strain and use as a vaccine
granted -
US 10548860
HIF-1 modulator paint formulation and uses thereof
granted -
US 10548948
Methods of treating fungal infections
granted -
US 10548946
Therapeutic compositions for neutralizing type I interferons, and methods of use
granted -
US 10544406
Characterization of four prophage endolysins specific for clostridium perfringens
granted -
US 10544085
Oils having antibacterial activity
granted -
US 10543268
Genetically engineered swine influenza virus and uses thereof
granted -
US 10544392
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
granted -
US 10543257
Lentiviral vector for treating hemoglobin disorders
granted -
US 10538590
Photosensitizing antibody-fluorophore conjugates
granted -
US 10537577
Compounds and compositions for ossification and methods related thereto
granted -
US 10538749
Mutant OPAA enzymes with increased catalytic efficiency on cyclosarin
granted -
US 10531654
Methods and compositions for vein harvest and autografting
granted -
US 10532022
Whole stablized olive mill process water, production thereof and uses thereof
granted -
US 10526297
Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
granted -
US 10525123
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
granted -
US 10525101
Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
granted -
US 10517920
Antibacterial peptide and method of treatment using the antibacterial peptide
granted -
US 10519222
Broadly neutralizing monoclonal antibodies against HIV-1 V1V2 Env region
granted -
US 10517890
Triggering RNA interference with RNA-DNA and DNA-RNA nanoparticles
granted -
US 10512673
Use of peptide-based inhibitors of the stat3-IL10 pathway for treating bacterial infection and granulomatous disease
granted -
US 10513494
Methods, compounds, and compositions for anesthesia
granted -
US 10513521
Compositions and methods for inhibiting BMP
granted -
US 10513533
Tunicamycin related compounds with anti-bacterial activity
granted -
US 10513543
Antigen chimera, antigen composition, vaccine, method of preparing the same and cassette thereof
granted -
US 10512671
IL-24 to treat inflammatory diseases
granted -
US 10513542
Minicircle DNA vector vaccine platform for foot-and-mouth disease and methods thereof
granted
Frequently asked questions
How many patents does United Therapeutics Europe have?
3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do United Therapeutics Europe patents expire?
234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources ยท Patent directory